Harnessing Soluble NK Cell Killer Receptors for Cancer Treatment
Author Information
Author(s): Arnon Tal, Markel Gal, Bar-Ilan Ahuva, Hanna Jacob, Fima Eyal, Benchetrit Fabrice, Galili Ruth, Cerwenka Adelheid, Benharroch Daniel, Sion-Vardy Netta, Porgador Angel, Mandelboim Ofer
Primary Institution: California Institute of Technology
Hypothesis
The NCR-Ig fusion proteins may be used as targeted agents for tumor therapy.
Conclusion
The NKp30-Ig fusion protein significantly inhibits tumor growth in prostate cancer models.
Supporting Evidence
- NKp30-Ig treatment resulted in a significant reduction in tumor size in both DU145 and PC3/Luc models.
- 50% of mice treated with NKp30-Ig showed complete tumor regression.
- NKp30-Ig enhanced macrophage-mediated killing of tumor cells in vitro.
Takeaway
Scientists created special proteins that help the immune system fight prostate cancer, and they found that one of these proteins worked really well in stopping tumors from growing.
Methodology
The study involved creating NK receptor-Ig fusion proteins and testing their effects on human prostate cancer cell lines in vivo using mouse models.
Limitations
The study does not address the potential effects of NKp30-Ig on healthy human cells.
Participant Demographics
The study used male nude mice for in vivo experiments.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website